See more : Enbridge Inc (ENB-PA.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Titan Medical Inc. (TMDI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Titan Medical Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- WAM Strategic Value Limited (WAR.AX) Income Statement Analysis – Financial Results
- Cummins Inc. (0I58.L) Income Statement Analysis – Financial Results
- ArcLight Clean Transition Corp. II (ACTD) Income Statement Analysis – Financial Results
- DH Enchantment Inc. (ENMI) Income Statement Analysis – Financial Results
- Victory Resources Corporation (VR.CN) Income Statement Analysis – Financial Results
Titan Medical Inc. (TMDI)
About Titan Medical Inc.
Titan Medical Inc., a medical technology company, focuses on the development and commercialization of robotic assisted surgical technologies for application in minimally invasive surgery. It is developing the Enos system, a robotic single access surgical system that includes a surgeon-controlled patient cart comprising a 3D high-definition vision system and multi-articulating instruments for performing surgical procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body during surgical procedures. The company is headquartered in Toronto, Canada.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.09M | 20.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 58.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 20.09M | 20.00M | -58.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 37.96M | 7.94M | 51.42M | 32.86M | 12.90M | 22.58M | 38.21M | 10.68M | 5.35M | 4.64M | 12.48M | 1.57M | 158.77K | 1.44M | 150.91K |
| General & Administrative | 12.43M | 7.49M | 7.81M | 6.80M | 5.97M | 4.93M | 3.53M | 3.50M | 3.48M | 3.08M | 3.07M | 1.97M | 548.18K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 140.98K | -5.00 | 2.00 | 1.00 | -5.00 | 1.00 | -4.00 | -114.22K | 9.82K | 240.83K | 134.87K | 11.76K | 0.00 | 0.00 |
| SG&A | 12.43M | 7.63M | 7.81M | 6.80M | 5.97M | 4.93M | 3.53M | 3.50M | 3.37M | 3.09M | 3.31M | 2.11M | 559.94K | 692.32K | 132.00K |
| Other Expenses | 699.00K | 0.00 | 32.55K | 29.04K | 17.36K | 24.64K | 32.39K | 23.66K | 118.75K | 155.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 51.08M | 15.57M | 59.27M | 39.69M | 18.88M | 27.53M | 41.77M | 14.20M | 8.83M | 7.88M | 15.79M | 3.68M | 718.71K | 2.13M | 282.91K |
| Cost & Expenses | 51.08M | 15.80M | 59.73M | 38.71M | 19.43M | 27.81M | 42.64M | 14.77M | 9.13M | 7.85M | 15.89M | 3.72M | 741.82K | 2.15M | 303.09K |
| Interest Income | 73.00K | 29.14K | 115.58K | 288.30K | 17.44K | 7.54K | 88.64K | 305.29K | 59.16K | 87.26K | 93.11K | 33.80K | 28.16K | 16.69K | 0.00 |
| Interest Expense | 125.00K | 1.09M | 422.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 165.48K | 27.57K |
| Depreciation & Amortization | 699.00K | 236.84K | 32.56K | 29.04K | 17.36K | 24.64K | 32.39K | 23.66K | 289.47K | 132.65K | 95.68K | 41.41K | 23.11K | 19.19K | 20.19K |
| EBITDA | -13.98M | -22.86M | -41.45M | -22.61M | -33.57M | -23.30M | -41.38M | -13.43M | -8.78M | -7.63M | -15.70M | -3.65M | -690.55K | -2.12M | -282.91K |
| EBITDA Ratio | -69.57% | -114.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -14.68M | -23.09M | -41.48M | -22.64M | -33.59M | -23.32M | -41.41M | -13.45M | -9.07M | -7.76M | -15.80M | -3.69M | -713.66K | -2.14M | -303.09K |
| Operating Income Ratio | -73.05% | -115.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 16.19M | -1.09M | 10.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -14.80M | -24.18M | -41.91M | -22.64M | -33.59M | -23.32M | -41.41M | -13.45M | -9.07M | -7.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -73.67% | -120.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 56.00K | 1.09M | 422.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 165.48K | 27.57K |
| Net Income | -14.86M | -25.28M | -42.33M | -22.64M | -33.59M | -23.32M | -41.41M | -13.45M | -9.07M | -7.76M | -15.80M | -3.69M | -713.66K | -2.30M | -330.66K |
| Net Income Ratio | -73.95% | -126.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.22 | -0.38 | -1.38 | -1.36 | -4.25 | -4.77 | -11.92 | -4.29 | -3.87 | -3.63 | -8.73 | -2.58 | -0.64 | -2.94 | -8.50 |
| EPS Diluted | -0.22 | -0.38 | -1.38 | -1.36 | -4.25 | -4.77 | -11.92 | -4.29 | -3.87 | -3.63 | -8.73 | -2.58 | -0.64 | -2.94 | -8.50 |
| Weighted Avg Shares Out | 67.01M | 67.01M | 30.69M | 16.64M | 7.90M | 4.89M | 3.48M | 3.14M | 2.34M | 2.14M | 1.81M | 1.43M | 1.11M | 782.20K | 38.89K |
| Weighted Avg Shares Out (Dil) | 67.01M | 67.01M | 30.69M | 16.64M | 7.90M | 4.89M | 3.48M | 3.14M | 2.34M | 2.14M | 1.81M | 1.43M | 1.11M | 782.20K | 38.89K |
Titan Medical: Innovation Leader in Robotic-assisted, Single Access Surgery Technology
Robotic-assisted single access surgery might sound like a future pipe dream for the medical community, but the technology exists today, and Titan Medical Inc. (NASDAQ: TMDI; TSX: TMD) is paving the way to bringing its exciting technology to surgeons. Titan...
TMDI Stock Price: Over 9% Increase Pre-Market Explanation
The stock price of Titan Medical Inc. (NASDAQ: TMDI) increased by over 9% pre-market. This is why it happened.
Titan Medical Receives License Fee of $10 Million Upon Achievement of Milestone Under Medtronic Development Agreement
Completion of Second Technical Milestone Marks Third Achievement Under Development and License Agreement Completion of Second Technical Milestone Marks Third Achievement Under Development and License Agreement
Titan Medical Announces Addition of Deepak Basra as Vice President, Strategy and Business Development
TORONTO, May 24, 2021 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced the addition of Deepak Basra as...
Titan Medical's (TMDI) CEO David McNally on Q1 2021 Results - Earnings Call Transcript
Titan Medical's (TMDI) CEO David McNally on Q1 2021 Results - Earnings Call Transcript
Titan Medical Stock Price Increased Over 15% Pre-Market: Why It Happened
The stock price of Titan Medical (NASDAQ: TMDI) increased by over 15% pre-market. This is why it happened.
Titan Medical to Participate in Upcoming Investor Conferences
TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that, David McNally, President, CEO and Chairman and...
Titan Medical Issues Corporate Update
TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced a corporate update in conjunction with its presentation...
Titan Medical to Present at H.C. Wainwright Global Life Sciences Conference
TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that David McNally, President, CEO and Chairman of...
Titan Medical Announces Closing of US $23M Bought Deal Offering Including Full Exercise of Over-Allotment Option
TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it closed its previously announced offering of...
Source: https://incomestatements.info
Category: Stock Reports